Acorda Therapeutics
Acorda Therapeutics Presents Positive Data from Preclinical Studies of Neuregulins in Cardiac Function
Published in Cardiovascular Business Week, August 19th, 2008
Acorda Therapeutics, Inc. (Nasdaq: ACOR) presented data on the company's neuregulin molecule GGF2 demonstrating improved cardiac function in preclinical models of heart failure. The data also indicated that GGF2 provided more benefit than other neuregulin fragments that were also tested. In preclinical testing, neuregulins have shown the potential to reduce and even reverse dysfunction of congestive heart failure by strengthening and protecting heart muscle cells. Data on GGF2 were presented on July 29 at the Basic Cardiovascular Sciences Conference in Keystone, CO.
"GGF2 represents a potentially novel and exciting therapeutic approach to cardiac damage and heart...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
More Articles from Cardiovascular Business Week
- Abiomed, Inc.
Abiomed Announces Impella 2.5 Capacity Expansion Plans in Ireland - Alcoholism
Alcohol Consumption Declining, According to Results of New Study - Alkermes, Inc.
Alkermes Announces Approval of VIVITROL for the Treatment of Alcohol Dependence in Russia - Angioplasty
Virtua Cardiologists Respond to Commentary on Angioplasty - Arrhythmia
Urologists Should Recognize the Cardiac Safety of Prescribed Medications, Article Concludes - Atherosclerosis Therapy
Research from Technion, Faculty of Medicine has provided new information about atherosclerosis therapy - More from this issue of Cardiovascular Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
